At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Intravitreal Aflibercept Injectiondrug
Likely dose
Intravitreal Aflibercept Injection 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study
In Brief
A Phase 2 clinical trial evaluating Intravitreal Aflibercept Injection for Central Serous Chorioretinopathy. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Serous Chorioretinopathy
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedOct 2012
Primary CompletionJun 2013
TodayJul 2026
First PostedOct 19, 2012
Enrollment StartOct 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.7 years ago
Interventions
Intravitreal Aflibercept Injectiondrug
GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total). GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total).